Company Filing History:
Years Active: 2016
Title: The Innovations of Jae-Kyun Ko in Pro-Apoptotic Polypeptides
Introduction
Jae-Kyun Ko, an accomplished inventor based in Piscataway, NJ, has made significant contributions to the field of biotechnology. His innovative work centers around the development of nucleic acid sequences that encode pro-apoptotic polypeptides, which have important applications in medical research and therapeutic treatments.
Latest Patents
Jae-Kyun Ko holds a patent for "ATAP peptides, nucleic acids encoding the same and associated methods of use." This pivotal invention includes a range of nucleic acid sequences that encode polypeptides aimed at promoting apoptosis in cells. The patent also describes antibodies that specifically bind to these polypeptides, as well as their derivatives, variants, mutants, or fragments. Additionally, the invention outlines various therapeutic, diagnostic, and research methodologies for diagnosing, treating, and preventing proliferative disorders and bacterial infections using the nucleic acids and proteins derived from this work.
Career Highlights
Jae-Kyun Ko is affiliated with Rutgers, The State University of New Jersey, where he continues to advance his research and explore innovative solutions in the life sciences. His dedication to the scientific community is evidenced by his active participation in research projects focused on improving health outcomes.
Collaborations
Throughout his career, Jae-Kyun Ko has collaborated with notable colleagues such as Jianjie Ma and Chul-Woo Kim. These partnerships have enhanced the scope of his research and contributed to the development of groundbreaking discoveries in the field.
Conclusion
Jae-Kyun Ko's work exemplifies the transformative power of innovation in biotechnology. His patent on pro-apoptotic polypeptides is a testament to his commitment to enhancing medical research and developing effective therapeutic methods. Through his collaborations and ongoing research at Rutgers, he continues to make significant strides that could lead to better treatment options for proliferative disorders and bacterial infections.